D-亮氨酸叔丁酯盐酸盐 | 67617-35-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-亮氨酸叔丁酯盐酸盐
• 中文别名: D-亮氨酸叔丁酯
• 英文名称: D-leucine t-butyl ester
• 英文别名: H-D-Leu-O-tBu；D-Leu-O-t-Bu；d-Leu-OtBu；(R)-tert-Butyl 2-amino-4-methylpentanoate；tert-butyl (2R)-2-amino-4-methylpentanoate
• CAS: 67617-35-0
• 化学式: C₁₀H₂₁NO₂
• mdl: MFCD10568783
• 分子量: 187.282
• InChiKey: HBEJJYHFTZDAHZ-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 储存条件：
  0-6°C

反应信息

• 作为反应物：
  描述：

  D-亮氨酸叔丁酯盐酸盐 在 N-甲基吗啉 、 sodium tetrahydroborate 、 铁粉 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 (R)-2-[7-(3,5-Dimethoxy-benzylamino)-1,1-dioxo-1,3,4,5-tetrahydro-1λ6-benzo[f][1,2,5]thiadiazepin-2-yl]-4-methyl-pentanoic acid benzyloxy-amide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors

  摘要：

  Elevated levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with several inflammatory diseases, and therefore, strategies for its suppression have become important targets in drug discovery. Our efforts to suppress TNF-alpha have centered on the inhibition of TNF-alpha converting enzyme (TACE) through the use of hydroxamate inhibitors. Starting from broad-spectrum matrix metalloproteinase (MMP) inhibitors, we have designed and synthesized novel benzothiadiazepines as potent and selective TACE inhibitors. The benzothiadiazepines were synthesized with variation in P1 and P1' in order to effect potency and selectivity. The inhibitors were evaluated versus porcine TACE (pTACE), and the initial selectivity was assessed with counterscreens of MMP-1, -2, and -9. Several potent and selective inhibitors were discovered with compound 41 being the most active against pTACE (K-i = 5 nM) while still maintaining good selectivity versus the MMP's (at least 75-fold). Most compounds were assessed in the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA) to determine their ability to suppress TNF-alpha. Compound 32 was the most potent compound in the PBMC assay (IC50 = 0.35 muM), while compound 62 was the most active in the WBA (IC50 = 1.4 muM).

  DOI：

  10.1021/jm020475w
• 作为产物：
  描述：

  tert-butyl 4-methyl-2-oxopentanoate 在 N-[4-[(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-[3-(2,4,6-trimethylphenyl)propoxy]methyl]quinolin-6-yl]-2,4,6-triethylbenzenesulfonamide 、 邻氯苯甲胺 、 盐酸 作用下， 以 苯 、 四氢呋喃 为溶剂， 反应 60.0h， 以61%的产率得到D-亮氨酸叔丁酯盐酸盐
  参考文献：
  名称：

  从α-酮酯到手性α-氨基酯的高效不对称仿生转氨

  摘要：

  描述了一种有效的不对称仿生氨基转移的α-酮酯与奎宁衍生物作为手性碱。可以以高收率和对映选择性合成多种含有各种官能团的α-氨基酯。

  DOI：

  10.1021/ol302427d

文献信息

• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。
• NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150246136A1

  公开（公告）日：2015-09-03

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对靶向表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病，以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• Novel Binder-Drug Conjugates (ADCs) and Use of Same
  申请人：Lerchen Hans-Georg

  公开号：US20140127240A1

  公开（公告）日：2014-05-08

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
  申请人：Lerchen Hans-Georg

  公开号：US20130066055A1

  公开（公告）日：2013-03-14

  The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及针对C4.4a靶点的新结合物-药物共轭物（ADCs），以及这些ADCs的活性代谢物，制备这些ADCs的方法，使用这些ADCs治疗和/或预防疾病，以及使用这些ADCs生产治疗和/或预防疾病的药物，更具体地说是治疗和/或预防高增殖和/或血管生成性疾病，例如癌症等。这种治疗可以作为单独治疗，也可以与其他药物或进一步的治疗措施结合使用。
• Stereocontrolled [¹¹ C]Alkylation of N-Terminal Glycine Schiff Bases To Obtain Dipeptides
  作者：Ulrike Filp、Aleksandra Pekošak、Alex J. Poot、Albert D. Windhorst

  DOI：10.1002/ejoc.201701129

  日期：2017.10.10

  stereoselective radiochemical [11C]alkylation to obtain functionalized dipeptides. We herein report a broadly applicable procedure for the asymmetric [11C]alkylation of dipeptides to give labeled N-terminal peptides by using different [11C]alkyl halides. Contended stereoselectivities of the reactions were observed by using 11C-labeled alkyl halides, [11C]methyl iodide and [11C]benzyl iodide, and diastereomeric

  使用各种季铵盐作为手性相转移催化剂可以进行有效的立体选择性放射化学 [11C] 烷基化，以获得功能化的二肽。我们在此报告了一种广泛适用的程序，用于二肽的不对称 [11C] 烷基化，通过使用不同的 [11C] 烷基卤化物得到标记的 N 端肽。通过使用 11C 标记的烷基卤化物、[11C] 甲基碘和 [11C] 苄基碘，观察到反应的立体选择性，并分别实现了 95:5 和 90:10 的不同专用催化剂的非对映体比例。因此，对映体富集化合物的直接合成应该在基于肽的放射性药物开发和正电子发射断层扫描成像中发挥重要作用。